TRAIL functional blockade by systemic administration of sDR5 was shown to exacerbate cyclophosphamide-induced diabetes in NOD mice, augment the severity of pancreatic islet inflammation (insulitis), and enhance the T1DM-specific immune response driven by anti-GAD65 autoantibodies [15]. The gene discussed is TNFSF10; the disease is type 1 diabetes mellitus.